drugset / Trial / NCT06460506

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older

NCT06460506

Phase 3 Active not recruiting 50 enrolled Vertex Pharmaceuticals Incorporated
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the long-term safety, tolerability, efficacy, and pharmacodynamics (PD) of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA).

Timeline

Start
2024-11-21
Primary completion
2027-09-30
Completion
2027-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivacaftor Other / unclassified Oral
Subject elexacaftor Small molecule Oral
Subject tezacaftor Other / unclassified Oral

Indications